Gross Profit Comparison: AstraZeneca PLC and Novartis AG Trends

A Decade of Gross Profit Trends: AstraZeneca vs. Novartis

In the ever-evolving pharmaceutical industry, AstraZeneca PLC and Novartis AG have been key players, each with a unique trajectory over the past decade. From 2014 to 2023, AstraZeneca's gross profit surged by approximately 86%, reflecting its strategic innovations and market expansions. In contrast, Novartis AG experienced a more modest growth of around 5% during the same period, maintaining a steady presence in the market.

AstraZeneca's Growth Spurt

AstraZeneca's gross profit saw a significant increase, particularly from 2020 onwards, with a notable jump of 50% from 2020 to 2023. This growth can be attributed to successful product launches and strategic acquisitions.

Novartis' Steady Path

While Novartis AG's growth was less dramatic, it remained consistent, peaking in 2021. Despite a slight decline in 2023, Novartis continues to hold a strong position in the global market.